Rein Therapeutics Inc (RNTX)

$1.91 +0.08 (4.37%)
Market Cap 40.25M
Revenue (ttm) 0.00
Net Income (ttm) -62.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 66,600
Avg Vol 36,898
Day's Range N/A - N/A
Shares Out 21.99M
Stochastic %K 97%
Beta 2.12
Analysts Strong Sell
Price Target $9.33

Latest News on RNTX

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 23, 2025, 7:00 AM EDT - 2 days ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 15, 2025, 7:00 AM EDT - 10 days ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 4:17 PM EDT - 18 days ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update